Accordingly, refeeding after a fast activates NE-expressing/CCK-expressing NTS neurons [61], CGRP-expressing lPBN neurons [63], and PKC-delta-expressing CeA neurons [62]
Injectable use in humans represents off-label experimental application with limited long-term human safety data specifically for injectable formulations
Glucagon in disease Hyperglucagonaemia contributes to a variety of diseases Hyperglucagonaemia has been reported in various diseases/conditions including type 2 diabetes, type 1 diabetes, obesity, fatty liver diseases and kidney diseases [22]
If you are planning pregnancy, remember to stop semaglutide at least 2 months before conception and discuss alternative diabetes management strategies with your healthcare team
In a model of non-ischemic HF in dogs (tachycardiomyopathy induced by pacemakers), IV infusion of GLP-1 increases left ventricular (LV) contractility (LV dP/dt increased by 98%, stroke volume by 102%, and cardiac output by 57%) and decreases LV end-diastolic pressure, heart rate, and systemic vascular resistance